BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wadman RI, van der Pol WL, Bosboom WM, Asselman FL, van den Berg LH, Iannaccone ST, Vrancken AF. Drug treatment for spinal muscular atrophy type I. Cochrane Database Syst Rev 2019;12:CD006281. [PMID: 31825542 DOI: 10.1002/14651858.CD006281.pub5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Schmitz D, Henn W. The fetus in the age of the genome. Hum Genet 2021. [PMID: 34426855 DOI: 10.1007/s00439-021-02348-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Pettersen K, Bunt C. How does intrathecal injected nusinersen compare with sham procedure for infants with spinal muscular atrophy (SMA) type I? Cochrane Clinical Answers 2021. [DOI: 10.1002/cca.3667] [Reference Citation Analysis]
3 Messina S, Sframeli M. New Treatments in Spinal Muscular Atrophy: Positive Results and New Challenges. J Clin Med 2020;9:E2222. [PMID: 32668756 DOI: 10.3390/jcm9072222] [Cited by in Crossref: 55] [Cited by in F6Publishing: 59] [Article Influence: 27.5] [Reference Citation Analysis]
4 Chen TH. New and Developing Therapies in Spinal Muscular Atrophy: From Genotype to Phenotype to Treatment and Where Do We Stand? Int J Mol Sci. 2020;21. [PMID: 32392694 DOI: 10.3390/ijms21093297] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 17.0] [Reference Citation Analysis]
5 Wadman RI, van der Pol WL, Bosboom WM, Asselman FL, van den Berg LH, Iannaccone ST, Vrancken AF. Drug treatment for spinal muscular atrophy types II and III. Cochrane Database Syst Rev. 2020;1:CD006282. [PMID: 32006461 DOI: 10.1002/14651858.cd006282.pub5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]